Efficacy of Esophageal Cancer Postoperative Adjuvant Treatment, Peptide Vaccine Treatment, Elucidated 5-year Survival Rate Approx. Doubled for Esophageal Cancer Patients - Kindai University
Press releases • Sep 01, 2020 00:50 UTC
Kindai University’s Faculty of Medicine has, in a world first, shown the efficacy of cancer-specific vaccine therapy as a postoperative adjuvant therapy in a phase 2 clinical trial. Administration of cancer-specific vaccine therapy roughly doubled the 5-year survival rate of advanced esophageal cancer patients. Vaccine therapy amplifying CTL2 is expected to help validate peptide vaccine therapy.